Skip to main content
SpringerLink
Log in

Berdazimer Topical Gel, 10.3%: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Berdazimer topical gel, 10.3% (ZELSUVMI™) is a nitric oxide (NO) releasing topical gel developed by Novan Inc. (a Ligand Pharmaceuticals company) for the treatment of molluscum contagiosum (MC). Novan has used their proprietary NO-based technology platform (NITRICIL™), which stores gaseous NO species on large polymers, in the development of berdazimer topical gel, 10.3%. In January 2024, berdazimer topical gel, 10.3% was approved for the topical treatment of MC in adult and paediatric patients 1 year of age and older in the USA. This article summarizes the milestones in the development of berdazimer topical gel, 10.3% leading to this first approval for the treatment of MC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Eichenfield L, Hebert A, Mancini A, et al. Therapeutic approaches and special considerations for treating molluscum contagiosum. J Drugs Dermatol. 2021;20(11):1185–90.

    Article  PubMed  Google Scholar 

  2. Lacarrubba F, Micali G, Trecarichi AC, et al. New developing treatments for molluscum contagiosum. Dermatol Ther (Heidelb). 2022;12(12):2669–78.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Olsen JR, Gallacher J, Finlay AY, et al. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15(2):190–5.

    Article  PubMed  Google Scholar 

  4. Oza VS. Molluscum contagiosum therapeutics—new options may be around the corner. JAMA Dermatol. 2022;158(8):863–4.

    Article  PubMed  Google Scholar 

  5. US Food & Drug Administration. FDA approves first treatment for molluscum contagiosum [media release]. 24 Jul 2023. https://www.fda.gov/.

  6. Sugarman JL, Hebert A, Browning JC, et al. Berdazimer gel for molluscum contagiosum: an integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 2023;00(00):1–10.

    Google Scholar 

  7. Maeda-Chubachi T, Hebert D, Messersmith E, Siegfried EC. SB206, a nitric oxide-releasing topical medication, induces the beginning of the end sign and molluscum clearance. JID Innov. 2021;1(3):1–8.

    Article  Google Scholar 

  8. Del Rosso JQ, Kircik J. Spotlight on the use of nitric oxide in dermatology: What is it? What does it do? Can it become an important addition to the therapeutic armamentarium for skin disease? J Drugs Dermatol. 2017;16(1 Suppl):s4–10.

    PubMed  Google Scholar 

  9. Banerjee NS, Moore DW, Wang HK, et al. NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions. Antiviral Res. 2019;170(00):1–9.

    Google Scholar 

  10. Cartwright M, Enloe C, Stripling S, Maeda-Chubachi T. Pharmacokinetic profile, safety, and tolerability of topical berdazimer gel, 10.3% in patients with molluscum contagiosum. J Drugs Dermatol. 2022;21(10):1104–10.

    Article  PubMed  Google Scholar 

  11. Novan Inc. Our Science: NITRICILTM. 2024. https://novan.com/our-science/. Accessed 31 Jan 2024.

  12. LNHC Inc. ZELSUVMI™ (berdazimer topical gel, 10.3%): US prescribing information. 2024. https://zelsuvmi.com/. Accessed Jan 9, 2024

  13. Sato Pharmaceutical Co Ltd. Open-label study to evaluate the safety and tolerability of SB206 in Japanese patients with molluscum contagiosum. 2020. https://jrct.niph.go.jp/latest-detail/jRCT2031230123. Accessed 30 Jan 2024.

  14. Ligand Pharmaceuticals Inc. Ligand acquires assets of Novan, Inc. for $12.2 million [media release]. 27 Sep 2023. https://investor.ligand.com/.

  15. Ligand Pharmaceuticals Inc. Ligand acquires milestone and royalty rights to SB206 from Novan, Inc [media release]. 6 May 2019. https://investor.ligand.com/.

  16. Novan Inc. Novan expands nitric oxide dermatology business partnership with Sato in Japan [media release]. 8 Oct 2018. https://www.novan.com/.

  17. Browning JC, Enloe C, Cartwright M, et al. Efficacy and safety of topical nitric oxide-releasing berdazimer gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial. JAMA Dermatol. 2022;158(8):871–8.

    PubMed  PubMed Central  Google Scholar 

  18. Ward BM, Riccio DA, Cartwright M, Maeda-Chubachi T. The antiviral effect of berdazimer sodium on molluscum contagiosum virus using a novel in vitro methodology. Viruses. 2023;15(12):1–11.

    Article  Google Scholar 

  19. Stripling S, Hebert A, Enloe C, et al. Clinical development program of novel topical nitric oxide releasing medication berdazimer gel 10.3% for the once-daily treatment of molluscum contagiosum [abstract no. and poster]. In: SCALE 2022. 2022.

  20. Novan Inc. A phase 3 efficacy & safety of SB206 & vehicle gel for the treatment of MC (B-SIMPLE2). 2022. https://clinicaltrials.gov/. Accessed 1 Feb 2024.

  21. Novan Inc. A phase 3 randomized parallel group study comparing the efficacy & safety of SB206 & vehicle gel in the treatment of MC (B-SIMPLE1). 2022. https://clinicaltrials.gov/. Accessed 1 Feb 2024.

  22. Hebert AA, Siegfried EC, Durham T, et al. Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: a randomized clinical trial. J Am Acad Dermatol. 2020;82(4):887–94.

    Article  CAS  PubMed  Google Scholar 

  23. Ligand Pharmaceuticals Inc. U.S. Food and Drug Administration approves ZELSUVMI™ as a first-in-class medication for the treatment of molluscum contagiosum [media release]. 5 Jan 2024. https://investor.ligand.com/.

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Susan J. Keam

Authors
  1. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan J. Keam.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 189 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keam, S.J. Berdazimer Topical Gel, 10.3%: First Approval. Drugs 84, 363–368 (2024). https://doi.org/10.1007/s40265-024-02012-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-024-02012-9

Search

Navigation